Correlation Between Novo Nordisk and BetterLife Pharma

Can any of the company-specific risk be diversified away by investing in both Novo Nordisk and BetterLife Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Novo Nordisk and BetterLife Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Novo Nordisk AS and BetterLife Pharma, you can compare the effects of market volatilities on Novo Nordisk and BetterLife Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Novo Nordisk with a short position of BetterLife Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Novo Nordisk and BetterLife Pharma.

Diversification Opportunities for Novo Nordisk and BetterLife Pharma

0.25

Correlation Coefficient

Novo Nordisk  BetterLife Pharma

Modest diversification

The 3 months correlation between Novo and BetterLife is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Novo Nordisk AS and BetterLife Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BetterLife Pharma and Novo Nordisk is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Novo Nordisk AS are associated (or correlated) with BetterLife Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BetterLife Pharma has no effect on the direction of Novo Nordisk i.e., Novo Nordisk and BetterLife Pharma go up and down completely randomly.

Pair Corralation between Novo Nordisk and BetterLife Pharma

Considering the 90-day investment horizon Novo Nordisk AS is expected to under-perform the BetterLife Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Novo Nordisk AS is 4.66 times less risky than BetterLife Pharma. The stock trades about -0.1 of its potential returns per unit of risk. The BetterLife Pharma is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  7.50  in BetterLife Pharma on December 28, 2024 and sell it today you would lose (0.82) from holding BetterLife Pharma or give up 10.93% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Novo Nordisk AS  vs.  BetterLife Pharma

Novo Nordisk AS

Risk-Adjusted Performance

Very Weak

Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

BetterLife Pharma

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in BetterLife Pharma are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, BetterLife Pharma reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Novo Nordisk and BetterLife Pharma

The main advantage of trading using opposite Novo Nordisk and BetterLife Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Novo Nordisk position performs unexpectedly, BetterLife Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BetterLife Pharma will offset losses from the drop in BetterLife Pharma's long position.

The idea behind Novo Nordisk AS and BetterLife Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.